Bavarian Nordic mpox shot gains approval for adolescents in EU

seekingalpha09-19

The European Commission has approved Bavarian Nordic's (OTCPK:BVNRY)(OTCPK:BVNKF) mpox shot for adolescents between 12 and 17 years old. Approval was based on data from a clinical study of more than ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468619505?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1402040044/image_1402040044.jpg","is_english":true,"pubTime":"2024-09-19 22:38","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2468619505","market":"us","top_or_hot":-1,"title":"Bavarian Nordic mpox shot gains approval for adolescents in EU","media":"seekingalpha","content":"<div>\n<p>The European Commission has approved Bavarian Nordic's (OTCPK:BVNRY)(OTCPK:BVNKF) mpox shot for adolescents between 12 and 17 years old.  Approval was based on data from a clinical study of more than ...</p>\n\n<a href=\"https://seekingalpha.com/news/4151198-bavarian-nordic-mpox-shot-gains-approval-adoelescents-eu\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bavarian Nordic mpox shot gains approval for adolescents in EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBavarian Nordic mpox shot gains approval for adolescents in EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-19 22:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4151198-bavarian-nordic-mpox-shot-gains-approval-adoelescents-eu><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The European Commission has approved Bavarian Nordic's (OTCPK:BVNRY)(OTCPK:BVNKF) mpox shot for adolescents between 12 and 17 years old.  Approval was based on data from a clinical study of more than ...</p>\n\n<a href=\"https://seekingalpha.com/news/4151198-bavarian-nordic-mpox-shot-gains-approval-adoelescents-eu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4151198-bavarian-nordic-mpox-shot-gains-approval-adoelescents-eu","article_id":"2468619505","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1402040044/image_1402040044.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468619505","pubTimestamp":1726756703,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The European Commission has approved Bavarian Nordic's  mpox shot for adolescents between 12 and 17 years old.  Approval was based on data from a clinical study of more than 300 adolescents and 200 adults that found non-inferior immune responses and similar safety profile between both age groups after two standard doses of the MVA-BN vaccine.  MVA-BN was first approved by the European Medicines Agency in 202.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK6045":"建筑与工程","BK6520":"工商业服务概念","BVNRY":"Bavarian Nordic A/S","BVNKF":"Bavarian Nordic A/S","MR7.SI":"挪迪克","BK4156":"煤与消费用燃料"},"translate_title":"巴伐利亚北欧mpox疫苗获得欧盟青少年批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BVNKF":1,"BVNRY":1,"MR7.SI":1},"content_text":"The European Commission has approved Bavarian Nordic's (OTCPK:BVNRY)(OTCPK:BVNKF) mpox shot for adolescents between 12 and 17 years old.  Approval was based on data from a clinical study of more than 300 adolescents and 200 adults that found non-inferior immune responses and similar safety profile between both age groups after two standard doses of the MVA-BN vaccine.  MVA-BN was first approved by the European Medicines Agency in 202.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468619505"}